---
title: "Darzalex (daratumumab) in multiple myeloma: Pharmacology questions"
description: "Pharmacology questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Darzalex (daratumumab) work in multiple myeloma (mechanism of action)? What does the hyaluronidase in Darzalex Faspro do? What is the half-life of Darzalex (daratumumab)? What are the inactive ingredients in Darzalex and Darzalex Faspro? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Pharmacology questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## Mechanism

<a id="darzalex-mechanism-cd38"></a>

### How does Darzalex (daratumumab) work in multiple myeloma (mechanism of action)?

> “Daratumumab is a CD38-targeted monoclonal antibody, which is an immunotherapy that works with the immune system.
>
> Multiple myeloma cells can go unrecognized by the body, which allows them to grow.
>
> Daratumumab attaches itself to the CD38 protein on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
>
> Daratumumab directly kills multiple myeloma cells and/or allows the immune system to identify and destroy them. Because of the way daratumumab works, it may also affect normal cells.”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=Daratumumab%20is%20a%20CD38%2Dtargeted%20monoclonal,may%20also%20affect%20normal%20cells.)

> “CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface 
> of hematopoietic cells, including clonal plasma cells in multiple myeloma 
> and light chain (AL) amyloidosis, as well as other cell types. Surface CD38 
> has multiple functions, including receptor mediated adhesion, signaling, 
> and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ 
> human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth 
> of CD38 expressing tumor cells by inducing apoptosis directly through Fc 
> mediated cross linking as well as by immune-mediated tumor cell lysis through 
> complement dependent cytotoxicity (CDC), antibody dependent cell mediated 
> cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). 
> A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory 
> T cells (CD38+Tregs) and B cells (CD38+Bregs) are decreased by daratumumab.”

Source: [DARZALEX: DARZALEX FASPRO®, page 13, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=13)

<a id="darzalex-hyaluronidase"></a>

### What does the hyaluronidase in Darzalex Faspro do?

> “DARZALEX FASPRO<sup>®</sup> contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes.<sup>1</sup>”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=contains%20recombinant%20hyaluronidase%2C%20which%20mimics,in%20approximately%203%20to%205)

> “Hyaluronan is a polysaccharide found in the extracellular matrix of the 
> subcutaneous tissue. It is depolymerized by the naturally occurring enzyme 
> hyaluronidase. Unlike the stable structural components of the interstitial 
> matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase 
> increases permeability of the subcutaneous tissue by depolymerizing 
> hyaluronan. In the doses administered, hyaluronidase in DARZALEX FASPRO 
> acts locally. The effects of hyaluronidase are reversible and permeability of 
> the subcutaneous tissue is restored within 24 to 48 hours.”

Source: [DARZALEX: DARZALEX FASPRO®, page 13, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=13)

Note: The Support & Resources page also gives a half-life of 0.5 days for recombinant hyaluronidase, and the Dosing and Administration Guide gives a half-life in skin of less than 30 minutes; the Prescribing Information gives the 0.5-day half-life for hyaluronan.

## Pharmacokinetics

<a id="darzalex-half-life"></a>

### What is the half-life of Darzalex (daratumumab)?

> “Elimination
> Daratumumab clearance decreased with increasing dose and with multiple 
> dosing. The mean ± SD linear clearance was estimated to be 171.4 ±  
> 95.3 mL/day and the mean ± SD estimated terminal half-life associated with 
> linear clearance was 18 ± 9 days following administration of the approved 
> recommended dosage of DARZALEX as monotherapy. Terminal half-life was 
> similar when DARZALEX was administered as combination therapy.”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

> “Elimination
> Daratumumab is cleared by parallel linear and nonlinear saturable target 
> mediated clearances. The estimated mean (CV%) linear clearance of 
> daratumumab is 119 mL/day (59%) in patients with multiple myeloma and is 
> 210 mL/day (42%) in patients with light chain (AL) amyloidosis. The estimated 
> mean (CV%) elimination half-life associated with linear clearance is 20 days 
> (22%) in patients with multiple myeloma and 28 days (74%) in patients with 
> light chain (AL) amyloidosis.”

Source: [DARZALEX: DARZALEX FASPRO®, page 14, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=14)

Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information.

## Components

<a id="darzalex-inactive-ingredients"></a>

### What are the inactive ingredients in Darzalex and Darzalex Faspro?

> “DARZALEX<sup>®</sup> (daratumumab) injection is supplied as a colorless to pale yellow 
> preservative-free solution for intravenous use in a single-dose vial. The pH 
> is 5.5.
> Each DARZALEX 20 mL single-dose vial contains (NDC 57894-502-20) 400 mg 
> daratumumab, glacial acetic acid (3.7 mg), mannitol (510 mg), polysorbate 20 
> (8 mg), sodium acetate trihydrate (59.3 mg), sodium chloride (70.1 mg), and 
> Water for Injection, USP.
> Each DARZALEX 5 mL single-dose vial contains (NDC 57894-502-05) 100 mg 
> daratumumab, glacial acetic acid (0.9 mg), mannitol (127.5 mg), polysorbate 20 
> (2 mg), sodium acetate trihydrate (14.8 mg), sodium chloride (17.5 mg), and 
> Water for Injection, USP.
> Each DARZALEX 20 mL single-dose vial contains (NDC 57894-505-20) 400 mg 
> daratumumab, L-histidine (7 mg), L-histidine hydrochloride monohydrate 
> (32.6 mg), L-methionine (20 mg), polysorbate 20 (8 mg), sorbitol (1093 mg), and 
> Water for Injection, USP.
> Each DARZALEX 5 mL single-dose vial contains (NDC 57894-505-05) 100 mg 
> daratumumab, L-histidine (1.8 mg), L-histidine hydrochloride monohydrate 
> (8.2 mg), L-methionine (5 mg), polysorbate 20 (2 mg), sorbitol (273.3 mg), and 
> Water for Injection, USP.”

Source: [DARZALEX: DARZALEX®, page 10, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=10)

> “DARZALEX FASPRO<sup>®</sup> (daratumumab and hyaluronidase-fihj) injection is a 
> sterile, preservative-free, colorless to yellow, and clear to opalescent solution 
> supplied in a single-dose vial for subcutaneous administration.
> Each DARZALEX  FASPRO 15 mL single-dose vial contains 1,800 mg of 
> daratumumab and 30,000 units of hyaluronidase, L-histidine (4.9 mg), 
> L-histidine hydrochloride monohydrate (18.4 mg), L-methionine (13.5 mg), 
> polysorbate 20 (6 mg), sorbitol (735.1 mg), and Water for Injection, USP.”

Source: [DARZALEX: DARZALEX FASPRO®, page 13, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=13)

Note: Both passages are from the Description section of the Prescribing Information: the first for DARZALEX (intravenous), the second for DARZALEX FASPRO.

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
